Avacopan
- TRADE NAME: Tavneos (ChemoCentryx)
- INDICATIONS:
Adjunct for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy including glucocorticoids.
- CLASS: Complement receptor antagonist
- HALF-LIFE: 97.6 hours
FDA APPROVAL DATE: 10/07/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:CYP3A4 inducers, CYP3A4 inhibitors, Itraconazole, Rifampin
No adequate and well-controlled studies with avacopan in pregnant women to inform a drug-associated risk.
Hepatitis B virus reactivation, including life threatening hepatitis B, was observed in the
clinical program.
Avacopan does not eliminate glucocorticoid use.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 02/27/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
